尽管HLA匹配被认为是allo-HSCT结果的关键遗传预测因子,非HLA基因的遗传多态性,特别是在编码免疫调节蛋白的基因中,也被认为是与移植并发症发生相关的额外风险因素。本研究旨在对所有符合条件的队列研究进行系统评价和荟萃分析,以确定CTLA-4基因多态性的影响。包括rs231775,rs3087243,rs4553808,rs5742909和rs733618,关于接受allo-HSCT的患者的临床结果。
在PubMed中进行系统的文献检索,WebofScience,进行Scopus以确定相关研究,并提取了相关信息。计算效应大小(ES)和相应的95%置信区间(CI)以估计关联。
16项研究符合条件,并纳入荟萃分析。汇总结果表明,只有rs3087243的显性模型与慢性GVHD(cGVHD)显着相关,而其他SNP与总生存率无显著相关性,无病生存,复发,GVHD
我们的研究表明,第一次,关于CTLA-4多态性对allo-HSCT后结局的作用的综合荟萃分析。结果表明,CT60CTLA-4多态性可能是cGVHD的重要危险因素。
Although HLA matching is considered as a key genetic predictor of allo-HSCT outcomes, genetic polymorphisms in non-HLA genes, especially in genes encoding immunoregulatory proteins, have also been proposed as additional risk factors linked to the occurrence of transplant complications. This study aimed to carry out a systematic
review and meta-analysis from all eligible cohort studies to determine the effect of CTLA-4 gene polymorphisms, including rs231775, rs3087243, rs4553808, rs5742909, and rs733618, on clinical outcomes in patients receiving an allo-HSCT.
A systematic literature search in PubMed, Web of Science, and Scopus was performed to identify the relevant studies, and related information was extracted. The effect size (ES) and corresponding 95% confidence intervals (CIs) were calculated to estimate the association.
16 studies were eligible and included in the meta-analysis. The pooled results showed that only the dominant models of rs3087243 were significantly associated with chronic GVHD (cGVHD), while other SNPs were not significantly associated with overall survival, disease-free survival, relapse, and GVHD.
Our study represents, for the first time, a comprehensive meta-analysis on the role of CTLA-4 polymorphisms on outcomes after allo-HSCT. The results indicate that the CT60 CTLA-4 polymorphism could be a significant risk factor for cGVHD.